1[2]Sato T, Sasaki N, Seharaseyon J, O'Rourke B, Marban E. Selective pharmacological agents implicate mitochondrial but not sarcolemmal K (ATP) channels in ischemic cardioprotecion[J]. Circulation, 2000; 101(20):2418-23
2[3]Ichinose M, Yonemochi H, Sato T, Saikawa T. Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress[J]. Am J Physiol Heart Circ Physiol, 2003; 284(6):H2235-41
3[7]Minners J, Lacerda L, McCarthy J, Meiring JJ, Yellon DM, Sack MN. Ischemic and pharmacological preconditioning in Girardi cells and C2C12 myotubes induce mitochondrial uncoupling[J]. Circ Res, 2001;89(9):787-92
4[8]Murata M, Akao M, O'Rourke B, Marban E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection[J]. Circ Res, 2001;89(10):891-8
5[9]Holmuhamedov EL, Wang L, Terzic A. ATP-sensitive K+ channel openers prevent Ca2+ overload in rat cardiac mitochondria[J]. J Physiol, 1999;519(2):347-60
6[10]Lawrence CL, Billups B, Rodrigo GC, Standen NB. The KATP channel opener diazoxide protects cardiac myocytes during metabolic inhibition without causing mitochondrial depolarization or flavoprotein oxidation[J]. Br J Pharmacol, 2001;134(3):535-42
7[11]Grimmsmann T, Rustenbeck I. Direct effects of diazoxide on mitochondria in pancreatic B-cells and on isolated liver mitochondria[J]. Br J Pharmacol, 1998;123(5);781-8
8[12]Dzeja PP, Bast P, Ozcan C, Valverde A, Holmuhamedov EL, Van Wylen DG, et al. Targeting nucleotide-requiring enzymes: implications for diazoxide-induced cardioprotection[J]. Am J Physiol Heart Circ Physiol, 2003;284(4):H1048-56
9[1]Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D'Alonzo AJ, et al. Cardioprotective effectof diazoxide and its interaction with mitochondrial ATP-sensitive K-channels: possible mechanism of cardioprotection[J]. Circ Res, 1997;81(7):1072-82
